GO Main Menu Go Main Contents Go Bottom Menu

CelltrionHealthcare

gnb show

MENU

Gnb close

Press Release

VEGZELMA® (bevacizumab-adcd) receives preferred formulary status with Ventegra® for commercially insured patients VEGZELMA® (bevacizumab-adcd) receives preferred formulary status with Ventegra® for commercially insured patients 2023-12-11

VEGZELMA® (bevacizumab-adcd) receives preferred formulary status with Ventegra® for commercially insured patients   Ventegra® will list VEGZELMA®(bevacizumab-adcd) on its national formulary that serves more than 400 clients and more than 13 million members and patients in the U.S. Celltrion USA completes a contract ...

Celltrion USA announces distribution and incorporation of YUFLYMA® (adalimumab-aaty), a Humira® biosimilar, to CarePartners Specialty Pharmacy Cost Savings Programs Celltrion USA announces distribution and incorporation of YUFLYMA® (adalimumab-aaty), a Humira® biosimilar, to CarePartners Specialty Pharmacy Cost Savings Programs 2023-10-26

Celltrion USA announces distribution and incorporation of YUFLYMA® (adalimumab-aaty), a Humira® biosimilar, to CarePartners Specialty Pharmacy Cost Savings Programs YUFLYMA® (adalimumab-aaty) was first approved by the Food and Drug Administration on May ...

Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA™ (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA™ (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease 2023-10-23

Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA™ (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease ZYMFENTRA™ is the first and only FDA-approved subcutaneous (SC) formulation of i...

게시물 검색
  • 85
    Celltrion’s Monoclonal Antibody Treatment regdanvi..
    Celltrion’s Monoclonal Antibody Treatment regdanvimab, Approved by the European Commission for the Treatment of COVID-19 The European Commission (EC) granted marketing authorisation for Celltrion’s regdanvimab following positive…
    2021-11-15
  • 84
    Celltrion Receives CHMP Positive Opinion for regda..
    Celltrion Receives CHMP Positive Opinion for regdanvimab (CT-P59) as One of the First Monoclonal Antibodies Recommended as a Treatment for COVID-19 by the CHMP The CHMP positive opinion marks the first time a monoclonal antibody treatment …
    2021-11-12
  • 83
    Celltrion submits Marketing Authorisation Applicat..
    Celltrion submits Marketing Authorisation Application to the European Medicines Agency forregdanvimab(CT-P59), a monoclonal antibody treatment for COVID-19 ·The European Medicines Agency (EMA) accepted application for marketing authorisation …
    2021-10-05
  • 82
    Celltrion’s regdanvimab (CT-P59) becomes the first..
    Celltrion’s monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS) The approval marks the first time a monoclonal antibod…
    2021-09-18
  • 81
    Brazilian Health Regulatory Agency (ANVISA) grants..
    Brazilian Health Regulatory Agency (ANVISA) grants emergency use authorisation (EUA) for Celltrion’s monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) in Brazil Regdanvimab (CT-P59) receives emergency use authorisation from the Brazili…
    2021-08-12
  • 80
    Celltrion Healthcare’s anticancer therapeutics Her..
    Celltrion Healthcare’s anticancer therapeuticsHerzuma®(trastuzumab) andTruxima®(rituximab)win Brazilian tender for two consecutive years ·Celltrion Healthcare signs exclusive contract to supplyHerzuma®(trastuzumab) to the Federal Government i…
    2021-08-03
  • 79
    Celltrion’s monoclonal antibody treatment for COVI..
    Celltrion’s Monoclonal Antibody Treatment for COVID-19, regdanvimab (CT-P59), Demonstrates Strong Neutralising Activity Against Delta Variant Pre- clinical data for regdanvimab (CT-P59) demonstrates strong neutralising activity against the Delt…
    2021-07-16
  • 78
    Celltrion’s monoclonal antibody treatment for COVI..
    Celltrion’s monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59), demonstrates high efficacy in neutralising against SARS-CoV-2 variant first identified in Brazil (P.1) ·Pre-clinical data for Regdanvimab(CT-P59) shows significant reduc…
    2021-07-05
  • 77
    Celltrion announces positive top-line results from..
    Celltrion announces positive top-line results from global Phase III trial of regdanvimab (CT-P59), an anti-COVID-19 monoclonal antibody treatment Regdanvimab (CT-P59) (40mg/kg) achieved statistically significant and clinically meaningful result…
    2021-06-14
  • 76
    Celltrion Healthcare presents the first real-world..
    Celltrion Healthcare presents the first real-world data for Truxima®(biosimilar rituximab) in patients with diffuse large B-cell lymphoma at the EHA 2021 Virtual Congress The multi-country retrospective post-approval study is the first to inves…
    2021-06-12